<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this 12-week, randomized, double-blind, placebo-controlled trial, the efficacy and safety of transglucosidase (TGD) were compared with placebo in patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="1" pm="."><plain>At 12 weeks, TGD 300 mg/day and TGD 900 mg/day significantly reduced HbA1c (0.18 and 0.21%) and insulin concentration (19.4 and 25.0 pmol/l), respectively, vs. placebo </plain></SENT>
<SENT sid="2" pm="."><plain>TGD 300 mg/day and TGD 900 mg/day also significantly reduced <z:chebi fb="1" ids="47774">low-density lipoprotein cholesterol</z:chebi> (0.22 and 0.17 mmol/l, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>TGD 900 mg/day significantly reduced <z:chebi fb="0" ids="17855">triglyceride</z:chebi> by 0.24 mmol/l and diastolic blood pressure by 8 mmHg </plain></SENT>
<SENT sid="4" pm="."><plain>Placebo was associated with a significant increase from baseline in body mass index, alanine aminotransferase and <z:chebi fb="0" ids="29995">aspartate</z:chebi> aminotransferase (0.17 kg/m(2) , 3 and 2 U/l, respectively), whereas TGD was not </plain></SENT>
<SENT sid="5" pm="."><plain>TGD 300 mg/day significantly increased high-molecular-weight adiponectin by 0.6 Âµg/ml </plain></SENT>
<SENT sid="6" pm="."><plain>Adverse events did not differ significantly between the groups </plain></SENT>
<SENT sid="7" pm="."><plain>TGD resulted in lowering of HbA1c and blood insulin level and improvements in metabolic and <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> in T2DM </plain></SENT>
</text></document>